Climara Pro (ESTRADIOL AND LEVONORGESTREL)
Climara Pro (ESTRADIOL AND LEVONORGESTREL) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Climara Pro; Generic name: ESTRADIOL AND LEVONORGESTREL; Drug class: Estrogen [EPC].
| Brand name | Climara Pro |
|---|---|
| Generic name | ESTRADIOL AND LEVONORGESTREL |
| Drug class | Estrogen [EPC] |
| Manufacturer | Bayer HealthCare Pharmaceuticals Inc. |
| Used for | 1 INDICATIONS AND USAGE Climara Pro is indicated for: Climara Pro is an estrogen plus progestin indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Prevention of Postmenopausal Osteoporosis ( 1.2 ) Limitations of Use: When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, fi |
| Dosage | 2 DOSAGE AND ADMINISTRATION Use estrogen-alone, or in combination with a progestogen, at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual women. Reevaluate postmenopausal women periodically as clinically appropriate to determine if treatment is still necessary. One Climara Pro transdermal system is available for use. Apply Climara Pro 0.045 mg per day/0.015 mg per day once-weekly to the lower abdomen ( 2.3 ) 2.1 Treatment of Mod |
| Warnings | WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined |
| Active ingredient(s) | ESTRADIOL |
| Route | TRANSDERMAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=184d3092-7fc6-4375-816b-1ab06bb99cfd |